In September, BOM invested in Cantoni Therapeutics from Oss. This biotech company is developing drugs that inhibit a specific enzyme: NNMT. This enzyme is particularly overactive in patients with overweight, insulin resistance, or cardiometabolic diseases and can negatively contribute to these disease processes.
With innovative molecules, Cantoni Therapeutics hopes to reduce the negative impact of NNMT on metabolism and contribute to improved patient outcomes.
Remedy for rheumatoid arthritis
Much more is happening at Pivot Park in Oss. For instance, Citryll made a significant leap forward. The first patient was treated in a clinical trial to validate the drug Citryll is developing against rheumatoid arthritis. A total of approximately 88 patients will participate, with a treatment period of 6 weeks.
On the international front, Brabant entrepreneurs are also expanding their influence. For instance, Sirius Medical announced an expansion of their collaboration with Mammotome, making the Sirius Pintuition system more accessible to healthcare providers in Poland and Italy.
That system helps surgeons accurately locate where a tumor is. This is especially useful for people with non-palpable tumors, which are tumors that are not easy to feel. Instead of using a wire or radioactive marker, Pintuition works with a small magnetic marker that can be placed in or near a tumor before the operation.
A silk membrane
Meanwhile, VIVOLTA strengthened its position by entering into a long-term production partnership with the German company Fibrothelium GmbH, focused on the production of SimplySilk membrane for bone regeneration.
That silk membrane forms a barrier that ensures gum tissue stays away from a bone defect, allowing the bone to heal and regenerate undisturbed. The membrane is resorbable, meaning it is broken down and absorbed by the body over time.
Additionally, companies are drawing attention with research and technological achievements. A study in the American Journal of Surgical Pathology confirmed that the Histolog Scanner from SamanTree Medical provides exceptionally accurate results in detecting breast cancer margins.
Learn more
Personalized medicine
InnoSIGN has meanwhile launched a portal that can identify pathogens through gene expression data, an important step towards more personalized medicine.
In the InnoSIGN portal, researchers can upload and analyze their gene expression data (RNA data) to discover which biological processes drive a disease. This helps to extract clear and useful insights from complex data about which mechanisms are important in a disease, which can be useful for research and drug development.
Multiple Brabant companies finalist
The innovative power from Brabant was also recognized internationally. For example, STENTiT was selected as a finalist from nearly 1,500 entries during The Medtech Conference in San Diego. Avidicure, Citryll, Salvia BioElectronics, and Synaffix were nominated for the prestigious Lifestars Awards.
Finally, Microsure strengthened its governance by appointing Michel Therin as the new chairman of the supervisory board. This positions the company for the next phase of growth.
Breeding ground for medical innovations
These developments show how Brabant is increasingly positioning itself as a breeding ground for medical innovations. Thanks to the support of BOM and the collaboration between entrepreneurs, knowledge institutions, and healthcare partners, groundbreaking ideas are being translated more quickly into concrete solutions for patients.
The past quarter demonstrates that the combination of entrepreneurship and support leads to tangible results. And that the Brabant Life Sciences & Medtech sector counts internationally.
Related news articles
